Clinical trial
A Randomized Phase III Trial of Hyperthermic Isolated Limb Perfusion With…
NCT00001296 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00001296 |
|---|---|
| Title | A Randomized Phase III Trial of Hyperthermic Isolated Limb Perfusion With Melphalan, Tumor Necrosis Factor, and Interferon-Gamma in Patients With Locally Advanced Extremity Melanoma |
| Official title | A Randomized Phase III Trial of Hyperthermic Isolated Limb Perfusion With Melphalan, Tumor Necrosis Factor, and Interferon-Gamma in Patients With Locally Advanced Extremity Melanoma |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Melanoma |
| Intervention type | Drug, Procedure |
| Interventions | melphalan, tumor necrosis factor, interferon-gamma, hyperthermic isolated limb perfusion |
| Enrollment | 122 |
| Start date | Feb 1, 1992 |
| Completion | Oct 1, 2000 |
| First posted | Dec 10, 2002 |
| Last update posted | Mar 4, 2008 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: